Issue 6
Jul 2022
Turn off MathJax
Article Contents
JOURNAL OF MECHANICAL ENGINEERING  > 2022  >  38(6): 574-579.
Li Y,Wang YY,Xing K,et al.Current situation and the latest progress in the treatment of pyoderma gangrenosum[J].Chin J Burns Wounds,2022,38(6):574-579.DOI: 10.3760/cma.j.cn501225-20220330-00108.
Citation: Li Y,Wang YY,Xing K,et al.Current situation and the latest progress in the treatment of pyoderma gangrenosum[J].Chin J Burns Wounds,2022,38(6):574-579.DOI: 10.3760/cma.j.cn501225-20220330-00108.
shu

Current situation and the latest progress in the treatment of pyoderma gangrenosum

doi: 10.3760/cma.j.cn501225-20220330-00108

  • Department of Dermatology, the First Hospital of Jilin University, Changchun 130021, China

More Information
  • Corresponding author: Li Shanshan, Email: lishans@jlu.edu.cn
  • Received Date: 30 Mar 2022
    Available Online: 12 Aug 2022
  • Issue Publish Date: 20 Jun 2022
    Abstract
  • Pyoderma gangrenosum (PG) is a rare chronic inflammatory non-infectious skin dermatosis, and there is no clear treatment guideline for this disease at home and abroad. There are a variety of clinical treatment methods for PG, including local therapy and systemic application of glucocorticoids, immunosuppressants, intravenous immuno- globulin, and biologics. Glucocorticoids are the first-line drugs commonly used in clinical practice, and immunosuppressants can be used alone or in combination with glucocorticoids. In recent years, more and more evidence has shown that biologics are a new trend in the treatment of PG, mainly including tumor necrosis factor α inhibitors, interleukin-1 (IL-1) inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, rituximab, and small molecular inhibitors. This article summarizes the current status and latest progress in the treatment of PG, hoping to provide clinicians with ideas for the treatment of PG.

     

    • FullText(HTML)
  • loading
    • References(53)
  • [1]
    Alonso-LeónT,Hernández-RamírezHH,Fonte-AvalosV,et al.The great imitator with no diagnostic test: pyoderma gangrenosum[J].Int Wound J,2020,17(6):1774-1782.DOI: 10.1111/iwj.13466.
    [2]
    von den DrieschP.Pyoderma gangrenosum: a report of 44 cases with follow-up[J].Br J Dermatol,1997,137(6):1000-1005.
    [3]
    JanowskaA,OrangesT,FissiA,et al.PG-TIME: a practical approach to the clinical management of pyoderma gangrenosum[J].Dermatol Ther,2020,33(3):e13412.DOI: 10.1111/dth.13412.
    [4]
    BraswellSF,KostopoulosTC,Ortega-LoayzaAG.Pathophysiology of pyoderma gangrenosum (PG): an updated review[J].J Am Acad Dermatol,2015,73(4):691-698.DOI: 10.1016/j.jaad.2015.06.021.
    [5]
    ViglK,PoschC,RichterL,et al.Pyoderma gangrenosum during pregnancy - treatment options revisited[J].J Eur Acad Dermatol Venereol,2016,30(11):1981-1984.DOI: 10.1111/jdv.13792.
    [6]
    YuYM,LaiFJ,FengC,et al.Pyoderma gangrenosum around an ileostoma: a case report[J].Medicine (Baltimore),2018,97(48):e13415.DOI: 10.1097/MD.0000000000013415.
    [7]
    谭谦,徐晔.慢性创面治疗的理论和策略[J].中华烧伤杂志,2020,36(9):798-802.DOI: 10.3760/cma.j.cn501120-20200728-00361.
    [8]
    AshchyanHJ,NelsonCA,StephenS,et al.Neutrophilic dermatoses: pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses[J].J Am Acad Dermatol,2018,79(6):1009-1022.DOI: 10.1016/j.jaad.2017.11.063.
    [9]
    CroitoruD,Naderi-AzadS,SachdevaM,et al.A wound care specialist's approach to pyoderma gangrenosum[J].Adv Wound Care (New Rochelle),2020,9(12):686-694.DOI: 10.1089/wound.2020.1168.
    [10]
    NahmWJ,MotaJA,RojasS,et al.Improvement of ulcerations in treatment-resistant chronic scarring in a patient with pyoderma gangrenosum after improving vascular insufficiency, gently removing necrotic debris, and decreasing wound fluid[J].Am J Case Rep,2018,19:844-848.DOI: 10.12659/AJCR.908995.
    [11]
    WinaikosolK, PunyavongP, JenwitheesukK, et al. Radiation ulcer treatment with hyperbaric oxygen therapy and haemoglobin spray:case report and literature review[J]. J Wound Care,2020,29(8):452-456. DOI: 10.12968/jowc.2020.29.8.452.
    [12]
    JiS,LiuX,HuangJ,et al.Consensus on the application of negative pressure wound therapy of diabetic foot wounds[J/OL].Burns Trauma,2021,9:tkab018[2022-03-30].https://pubmed.ncbi.nlm.nih.gov/34212064/.DOI: 10.1093/burnst/tkab018.
    [13]
    AhronowitzI,HarpJ,ShinkaiK.Etiology and management of pyoderma gangrenosum: a comprehensive review[J].Am J Clin Dermatol,2012,13(3):191-211.DOI: 10.2165/11595240-000000000-00000.
    [14]
    Rodríguez-ZúñigaMJM, HeathMS, GontijoJRV, et al. Pyoderma gangrenosum: a review with special emphasis on Latin America literature[J].An Bras Dermatol,2019,94(6):729-743.DOI: 10.1016/j.abd.2019.06.001.
    [15]
    MekkesJR.Treatment of pyoderma gangrenosum[J].BMJ,2015,350:h3175.DOI: 10.1136/bmj.h3175.
    [16]
    AhnC,NegusD,HuangW.Pyoderma gangrenosum: a review of pathogenesis and treatment[J].Expert Rev Clin Immunol,2018,14(3):225-233.DOI: 10.1080/1744666X.2018.1438269.
    [17]
    DinRS,TsiarasWG,LiDG,et al.Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review[J].J Drugs Dermatol,2018,17(10):1058-1060.
    [18]
    WollinaU.Pyoderma gangrenosum: a systemic disease?[J].Clin Dermatol,2015,33(5):527-530.DOI: 10.1016/j.clindermatol.2015.05.003.
    [19]
    WollinaU,TchernevG.Pyoderma gangrenosum: pathogenetic oriented treatment approaches[J].Wien Med Wochenschr,2014,164(13/14):263-273.DOI: 10.1007/s10354-014-0285-x.
    [20]
    McKenzieF,CashD,GuptaA,et al.Biologic and small-molecule medications in the management of pyoderma gangrenosum[J].J Dermatolog Treat,2019,30(3):264-276.DOI: 10.1080/09546634.2018.1506083.
    [21]
    MonkE,ShalitaA,SiegelDM.Clinical applications of non-antimicrobial tetracyclines in dermatology[J].Pharmacol Res,2011,63(2):130-145.DOI: 10.1016/j.phrs.2010.10.007.
    [22]
    JockenhöferF,WollinaU,SalvaKA,et al.The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum[J].Br J Dermatol,2019,180(3):615-620.DOI: 10.1111/bjd.16401.
    [23]
    SongH,LahoodN,MostaghimiA.Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series[J].Br J Dermatol,2018,178(2):363-368.DOI: 10.1111/bjd.15850.
    [24]
    KapetanovicI,TanasilovicS,LalosevicJ,et al.Refractory steroid-resistant pyoderma gangrenosum successfully treated with intravenous immunoglobulins[J].Dermatol Ther,2020,33(6):e14322.DOI: 10.1111/dth.14322.
    [25]
    TanMH,GordonM,LebwohlO,et al.Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody[J].Arch Dermatol,2001,137(7):930-933.
    [26]
    4thMcGowan JW,JohnsonCA,LynnA.Treatment of pyoderma gangrenosum with etanercept[J].J Drugs Dermatol,2004,3(4):441-444.
    [27]
    BrooklynTN,DunnillMG,ShettyA,et al.Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial[J].Gut,2006,55(4):505-509.DOI: 10.1136/gut.2005.074815.
    [28]
    RegueiroM,ValentineJ,PlevyS,et al.Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease[J].Am J Gastroenterol,2003,98(8):1821-1826.DOI: 10.1111/j.1572-0241.2003.07581.x.
    [29]
    AgarwalA,AndrewsJM.Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy[J].Aliment Pharmacol Ther,2013,38(6):563-572.DOI: 10.1111/apt.12431.
    [30]
    YamasakiK,YamanakaK,ZhaoY,et al.Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: twenty-six-week phase 3 open-label study[J].J Dermatol,2020,47(12):1383-1390.DOI: 10.1111/1346-8138.15533.
    [31]
    CinottiE,LabeilleB,PerrotJL,et al.Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis[J].Clin Exp Dermatol,2014,39(6):750-751.DOI: 10.1111/ced.12393.
    [32]
    HurabielleC,SchneiderP,BaudryC,et al.Certolizumab pegol - a new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn's disease[J].J Dermatolog Treat,2016,27(1):67-69.DOI: 10.3109/09546634.2015.1034075.
    [33]
    PenderTM,AyandibuG,Van VoorheesAS.Certolizumab for the treatment of localized pyoderma gangrenosum associated with Crohn's disease: a case report[J].Dermatol Ther,2020,33(6):e14352.DOI: 10.1111/dth.14352.
    [34]
    KoliosAG,MaulJT,MeierB,et al.Canakinumab in adults with steroid-refractory pyoderma gangrenosum[J].Br J Dermatol,2015,173(5):1216-1223.DOI: 10.1111/bjd.14037.
    [35]
    Ben AbdallahH,FoghK,VestergaardC,et al.Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review[J/OL].Dermatology,2021:1-8(2021-10-28)[2022-03-30]. https://pubmed.ncbi.nlm.nih.gov/34710873/.DOI:10.1159/000519320.[published online ahead of print].
    [36]
    McPhieML,KirchhofMG.Pyoderma gangrenosum treated with secukinumab: a case report[J].SAGE Open Med Case Rep,2020,8:2050313X20940430.DOI: 10.1177/2050313X20940430.
    [37]
    FletcherJ,AlhusayenR,AlaviA.Recent advances in managing and understanding pyoderma gangrenosum[J].F1000Res,2019,8:F1000 Faculty Rev-2092.DOI: 10.12688/f1000research.19909.1.
    [38]
    VavrickaSR,GalvánJA,DawsonH,et al.Expression patterns of TNFα, MAdCAM1, and STAT3 in intestinal and skin manifestations of inflammatory bowel disease[J].J Crohns Colitis,2018,12(3):347-354.DOI: 10.1093/ecco-jcc/jjx158.
    [39]
    OrfalyVE,KovalenkoI,TolkachjovSN,et al.Tofacitinib for the treatment of refractory pyoderma gangrenosum[J].Clin Exp Dermatol,2021,46(6):1082-1085.DOI: 10.1111/ced.14683.
    [40]
    ScheinbergM,MachadoLA,Castro LGM,et al.Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor[J].J Transl Autoimmun,2021,4:100099.DOI: 10.1016/j.jtauto.2021.100099.
    [41]
    DaCunhaM,SiscosS,DowningM,et al.Pyoderma gangrenosum controlled with rituximab[J].JAAD Case Rep,2019,5(7):593-595.DOI: 10.1016/j.jdcr.2019.04.019.
    [42]
    AggarwalP.Pyoderma gangrenosum adverse event with Rituximab use: a postmarketing pharmacovigilance analysis[J].Dermatol Ther,2020,33(2):e13221.DOI: 10.1111/dth.13221.
    [43]
    SotzenJR,StratmanEJ.Vulvovaginal pyoderma gangrenosum associated with rituximab use in 2 patients with rheumatoid arthritis[J].JAAD Case Rep,2021,10:75-77.DOI: 10.1016/j.jdcr.2021.02.013.
    [44]
    LuJD,MilakovicM,Ortega-LoayzaAG,et al.Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1[J].Expert Opin Investig Drugs,2020,29(11):1179-1185.DOI: 10.1080/13543784.2020.1819981.
    [45]
    SteeleRB,NugentWH,BraswellSF,et al.Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment[J].Br J Dermatol,2016,174(1):77-87.DOI: 10.1111/bjd.14230.
    [46]
    StieglerJD,LucasCT,SamiN.Pyoderma gangrenosum in pregnancy successfully treated with infliximab and prednisone[J].JAAD Case Rep,2017,3(5):387-389.DOI: 10.1016/j.jdcr.2017.03.016.
    [47]
    MottetC,VaderJP,FelleyC,et al.Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): results of a multidisciplinary international expert panel-EPACT II[J].J Crohns Colitis,2009,3(4):257-263.DOI: 10.1016/j.crohns.2009.03.008.
    [48]
    DjokanovicN,Klieger-GrossmannC,PupcoA,et al.Safety of infliximab use during pregnancy[J].Reprod Toxicol,2011,32(1):93-97.DOI: 10.1016/j.reprotox.2011.05.009.
    [49]
    KechichianE,HaberR,MouradN,et al.Pediatric pyoderma gangrenosum: a systematic review and update[J].Int J Dermatol,2017,56(5):486-495.DOI: 10.1111/ijd.13584.
    [50]
    PowellFC,PerryHO.Pyoderma gangrenosum in childhood[J].Arch Dermatol,1984,120(6):757-761.
    [51]
    CrouseL,McShaneD,MorrellDS,et al.Pyoderma gangrenosum in an infant: a case report and review of the literature[J].Pediatr Dermatol,2018,35(5):e257-e261.DOI: 10.1111/pde.13471.
    [52]
    MeredithJ,HendersonP,WilsonDC,et al.Combination immunotherapy use and withdrawal in pediatric inflammatory bowel disease-a review of the evidence[J].Front Pediatr,2021,9:708310.DOI: 10.3389/fped.2021.708310.
    [53]
    MarinoA,GianiT,CimazR.Risks associated with use of TNF inhibitors in children with rheumatic diseases[J].Expert Rev Clin Immunol,2019,15(2):189-198.DOI: 10.1080/1744666X.2019.1550359.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views(116) PDF downloads(0) Cited by()
    Proportional views
    Related

    Copyright © 2009《 石油钻探技术 》 All Rights Reserved.

    Address：North-Star Times Tower, No.8 Beichendong Road, Chaoyang District, Beijing, China China Pos：100101

    Tel：010-84988317，84988356，84988357 Fax：021-64253812 Email：syzt@vip.163.com

    Beijing public network security equipment 11010502036328　Beijing ICP backup 17033152

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return